4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	20.45	20.72	3.13	18.04	13.61	6.99
Revenue Growth (YoY)	826.31%	562.29%	-82.65%	32.52%	94.85%	-50.56%
Cost of Revenue	102.55	97.1	80.25	61.36	53.04	38.72
Gross Profit	-82.1	-76.37	-77.12	-43.32	-39.43	-31.73
Selling, General & Admin	38.8	36.49	32.91	28.01	17.24	13.9
Operating Expenses	38.8	36.49	32.91	28.01	17.24	13.9
Operating Income	-120.9	-112.87	-110.03	-71.33	-56.66	-45.63
Interest & Investment Income	16.51	12.21	2.57	0.14	0.15	1.5
Other Non Operating Income (Expenses)	-0.17	-0.18	-0.04	-0.12	-0.18	-0.05
EBT Excluding Unusual Items	-104.56	-100.84	-107.49	-71.32	-56.69	-44.17
Pretax Income	-104.56	-100.84	-107.49	-71.32	-56.69	-49.31
Net Income	-104.56	-100.84	-107.49	-71.32	-56.69	-49.31
Net Income to Common	-104.56	-100.84	-107.49	-71.32	-56.69	-49.31
Shares Outstanding (Basic)	43	39	32	28	6	5
Shares Outstanding (Diluted)	43	39	32	28	6	5
Shares Change (YoY)	33.24%	20.95%	16.66%	331.23%	25.05%	1.85%
EPS (Basic)	-2.42	-2.58	-3.32	-2.57	-8.82	-9.59
EPS (Diluted)	-2.42	-2.58	-3.32	-2.57	-8.82	-9.59
Free Cash Flow	-79.44	-78.56	-98.22	-78.24	-51.91	-39.91
Free Cash Flow Per Share	-1.84	-2.01	-3.04	-2.82	-8.07	-7.76
Gross Margin	-	-	-	-240.17%	-289.64%	-
Operating Margin	-591.10%	-544.65%	-3516.52%	-395.46%	-416.28%	-653.12%
Free Cash Flow Margin	-388.42%	-379.11%	-3139.05%	-433.77%	-381.35%	-571.34%
EBITDA	-116.55	-108.66	-107.63	-69.81	-55.22	-44.62
D&A For EBITDA	4.35	4.2	2.4	1.52	1.44	1
EBIT	-120.9	-112.87	-110.03	-71.33	-56.66	-45.63
Revenue as Reported	-	-	-	-	13.61	6.99

Source: S&P Capital IQ. Standard template.